Latest news
First-Line Treatment Intensification in EGFR-Mutated NSCLC: Overall Survival Data and Regimen Selection - OncLiveOncLive · Tue, 11 Aug 2026 03:35:15 GMTMechanism of Action of Amivantamab-Lazertinib in EGFR-Mutated NSCLC and the Biology of Resistance Prevention - OncLiveOncLive · Tue, 11 Aug 2026 03:35:14 GMTTP53 Co-Mutation in EGFR-Mutated NSCLC: Clinical Significance and Impact on Frontline Therapy Choice - OncLiveOncLive · Mon, 10 Aug 2026 23:39:17 GMTTP53-Mutated EGFR NSCLC: Powerful PFS Gain With Combination Therapy - OncodailyOncodaily · Mon, 10 Aug 2026 16:58:29 GMTKRAS-Mutant Lung Cancer: Unmet Needs Persist Beyond G12C, Expert Says - Targeted OncologyTargeted Oncology · Mon, 10 Aug 2026 13:07:11 GMTLCT Gains Ground in EGFR-Mutated NSCLC - OncLiveOncLive · Fri, 07 Aug 2026 14:05:45 GMTCommunity Adoption of Frontline Combination Regimens and Tolerability - OncLiveOncLive · Fri, 07 Aug 2026 03:26:14 GMTTreatment Strategies Following Progression in EGFR-Mutant NSCLC - OncLiveOncLive · Fri, 07 Aug 2026 01:41:15 GMT